Stockscreener 앱 받기
6.98
1.97%
-0.14
시간 외 거래:
6.98
전일 마감가:
$7.12
열려 있는:
$6.96
하루 거래량:
668.87K
Relative Volume:
0.53
시가총액:
$333.42M
수익:
-
순이익/손실:
$-59.85M
주가수익비율:
-7.8808
EPS:
-0.8857
순현금흐름:
$-54.54M
1주 성능:
-3.86%
1개월 성능:
+23.76%
6개월 성능:
+202.16%
1년 성능:
+417.04%
1일 변동 폭
$6.68
$7.22
1주일 범위
$6.68
$7.4465
52주 변동 폭
$1.05
$8.04
Climb Bio Inc Stock (CLYM) Company Profile
명칭
Climb Bio Inc
전화
1-866-857-2596
주소
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
6.98 | 340.11M | 0 | -59.85M | -54.54M | -0.8857 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-03-11 | 개시 | Raymond James | Strong Buy |
| 2026-03-05 | 개시 | Wedbush | Outperform |
| 2026-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-10-16 | 개시 | William Blair | Outperform |
| 2025-10-13 | 개시 | H.C. Wainwright | Buy |
| 2025-08-15 | 개시 | Robert W. Baird | Outperform |
| 2025-06-06 | 개시 | Oppenheimer | Outperform |
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
모두보기
Climb Bio Inc 주식(CLYM)의 최신 뉴스
Climb Bio (NASDAQ:CLYM) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - MSN
Climb Bio (CLYM) Receives 'Buy' Rating from Truist Securities | - GuruFocus
Truist initiates Climb Bio stock with buy rating on drug potential - Investing.com
Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - Yahoo Finance
HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings - Defense World
Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Raymond James initiates coverage of Climb Bio (CLYM) with strong buy recommendation - MSN
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings? - MarketBeat
Analysts’ Weekly Ratings Updates for Climb Bio (CLYM) - Defense World
Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026 - Meyka
Research Analysts Issue Forecasts for Climb Bio Q1 Earnings - Defense World
Climb Bio (NASDAQ:CLYM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for Climb Bio Issued By HC Wainwright - MarketBeat
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline - Investing.com UK
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline By Investing.com - Investing.com South Africa
Climb Bio (NASDAQ:CLYM) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Climb Bio (NASDAQ:CLYM) Price Target Raised to $15.00 - MarketBeat
Climb Bio price target raised to $11 from $9 at HC Wainwright - MSN
Climb Bio (NASDAQ:CLYM) Research Coverage Started at Wedbush - Defense World
Published on: 2026-03-08 04:23:03 - baoquankhu1.vn
HC Wainwright forecasts 2026 data readouts for Climb Bio’s (CLYM) Budoprutug across clinical tracks - MSN
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP) and Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
Fed Meeting: Is Climb Bio Inc a stock for growth or value investors2025 Biggest Moves & Consistent Income Trade Ideas - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Wedbush Raises Price Target for CLYM, Maintains 'Outperform' Rat - GuruFocus
Baird Maintains "Outperform" Rating, Raises Price Target for CLY - GuruFocus
Climb Bio (NASDAQ:CLYM) Price Target Raised to $12.00 - MarketBeat
Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target - Trefis
Investment Recap: What is the Moat Score of Climb Bio Inc2025 Growth vs Value & Real-Time Buy Signal Notifications - baoquankhu1.vn
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Sahm
Wedbush Begins Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
Wedbush initiates Climb Bio stock with Outperform rating By Investing.com - Investing.com Nigeria
Wedbush initiates Climb Bio stock with Outperform rating - Investing.com India
Wedbush Initiates Climb Bio at Outperform With $12 Price Target - marketscreener.com
Climb 2025 10-K: $0 Revenue, $(0.88) EPS and $59.9M Net Loss - TradingView
CLYM: Net loss narrowed to $59.9M in 2025 as clinical R&D spending accelerated - TradingView
Climb Bio (Nasdaq: CLYM) ends 2025 with $160.7M cash and key 2026 trial readouts ahead - Stock Titan
Aug PostEarnings: Does Climb Bio Inc offer margin of safetyJuly 2025 Highlights & Detailed Earnings Play Alerts - baoquankhu1.vn
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Insider Sell Alert: Stephen Thomas Sells 50,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference - MarketBeat
Climb Bio (CLYM) Price Target Increased by 20.30% to 11.66 - Nasdaq
Proposed 50,000-share sale by CLYM broker (CLYM) - Stock Titan
Climb Bio Inc (CLYM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):